12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 569-581

  Yeung, Jennifer ^a   Apopa, Patrick L ^a   Vesci, Joanne ^a   Stolla, Moritz ^a,e   Rai, Ganesha ^b   Simeonov, Anton ^b   Jadhav, Ajit ^b   Fernandez Perez, Pilar ^a   Maloney, David J ^b   Boutaud, Olivier ^d   Holman, Theodore R ^c   Holinstat, Michael ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

12 lipoxygenase; Aggregation; Eicosanoids; Platelet activation; Thrombosis

Indexed keywords

15 HYDROXY 11ALPHA, 9ALPHA EPOXYMETHANOPROSTA 5, 13 DIENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; COLLAGEN; CONVULXIN; CYCLOOXYGENASE 1; GLYCOPROTEIN VI; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; HUMAN CELL; MOUSE; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; BLOOD PLATELETS; CYCLOOXYGENASE 1; EICOSANOIDS; FLOW CYTOMETRY; HUMANS; MICE; MICE, TRANSGENIC; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, THROMBIN; THROMBOSIS; TIME FACTORS;

EID: 84883247945     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0014     Document Type: Article

References (51)

1. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-884.
2. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
3. Elwood PC, Renaud S, Sharp DS, et al. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991; 83: 38-44.
4. Lincoff AM. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 2003; 107: 1556-1559.
5. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
6. Marcus AJ. Aspirin as prophylaxis against colorectal cancer. N Engl J Med 1995; 333: 656-658.
7. Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 1974; 71: 3400-3404.
8. Marcus AJ. The role of lipids in platelet function: with particular reference to the arachidonic acid pathway. J Lipid Res 1978; 19: 793-826.
9. Funk CD, Furci L, FitzGerald GA. Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc Natl Acad Sci USA 1990; 87: 5638-5642.
10. Fonlupt P, Croset M, Lagarde M. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets. Thromb Res 1991; 63: 239-248.
11. Nyby MD, Sasaki M, Ideguchi Y, et al. Platelet lipoxygenase inhibitors attenuate thrombin-and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation. J Pharmacol Exp Ther 1996; 278: 503-509.
12. Ozeki Y, Ito H, Nagamura Y, et al. 12(S)-HETE plays a role as a mediator of expression of platelet CD62 (P-selectin). Platelets 1998; 9: 297-302.
13. Pidgeon GP, Lysaght J, Krishnamoorthy S, et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 2007; 26: 503-524.
14. Quintana LF, Guzman B, Collado S, et al. A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE. Kidney Int 2006; 69: 526-530.
15. Zink MH, Oltman CL, Lu T, et al. 12-lipoxygenase in porcine coronary microcirculation: implications for coronary vasoregulation. Am J Physiol Heart Circ Physiol 2001; 280: H693-704.
16. Yeung J, Apopa PL, Vesci J, et al. Protein kinase C regulation of 12-lipoxygenasemediated human platelet activation. Mol Pharmacol 2012; 81: 420-430.
17. Siegel MI, McConnell RT, Porter NA, et al. Arachidonate metabolism via lipoxygenase and 12L-hydroperoxy-5,8,10,14-icosatetraenoic acid peroxidase sensitive to anti-inflammatory drugs. Proc Natl Acad Sci USA 1980; 77: 308-312.
18. Ruzicka T. The role of the epidermal 12-hydroxyeicosatetraenoic acid receptor in the skin. Eicosanoids 1992; 5 (Suppl): S63-65.
19. Guo Y, Zhang W, Giroux C, et al. Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J Biol Chem 2011; 286: 33832-33840.
20. Herbertsson H, Kuhme T, Evertsson U, et al. Identification of subunits of the 650 kDa 12(S)-HETE binding complex in carcinoma cells. J Lipid Res 1998; 39: 237-244.
21. Liu B, Khan WA, Hannun YA, et al. 12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids. Proc Natl Acad Sci USA 1995; 92: 9323-9327.
22. Morgan AH, Dioszeghy V, Maskrey BH, et al. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. J Biol Chem 2009; 284: 21185-21191.
23. Akiba S, Murata T, Kitatani K, et al. Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation. Biol Pharm Bull 2000; 23: 1293-1297.
24. Brune B, Ullrich V. 12-hydroperoxyeicosatetraenoic acid inhibits main platelet functions by activation of soluble guanylate cyclase. Mol Pharmacol 1991; 39: 671-678.
25. Eynard AR, Galli G, Tremoli E, et al. Aspirin inhibits platelet 12-hydroxy-eicosatetraenoic acid formation. J Lab Clin Med 1986; 107: 73-78.
26. Johnson EN, Brass LF, Funk CD. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc Natl Acad Sci USA 1998; 95: 3100-3105.
27. Pidgeon GP, Tang K, Cai YL, et al. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Res 2003; 63: 4258-4267.
28. Raso E, Tovari J, Toth K, et al. Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase-and PKC-mediated serine phosphorylation events in melanoma cells. Thromb Haemost 2001; 85: 1037-1042.
29. Kaur G, Jalagadugula G, Mao G, et al. RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood 2010; 115: 3128-3135.
30. Deschamps JD, Gautschi JT, Whitman S, et al. Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem 2007; 15: 6900-6908.
31. Yeung J, Holinstat M. 12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovasc Hematol Agents Med Chem 2011; 9: 154-164.
32. Kenyon V, Rai G, Jadhav A, et al. Discovery of potent and selective inhibitors of human platelet-type 12-lipoxygenase. J Med Chem 2011; 54: 5485-5497.
33. Kenyon V, Chorny I, Carvajal WJ, et al. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. J Med Chem 2006; 49: 1356-1363.
34. Holinstat M, Boutaud O, Apopa PL, et al. Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2alpha differently for cyclooxygenase-1 and 12-lipoxygenase catalysis. Arterioscler Thromb Vasc Biol 2011; 31: 435-442.
35. Holinstat M, Voss B, Bilodeau ML, et al. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway. Mol Pharmacol 2007; 71: 686-694.
36. Holinstat M, Voss B, Bilodeau ML, et al. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. J Biol Chem 2006; 281: 26665-26674.
37. Neeves KB, Maloney SF, Fong KP, et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost 2008; 6: 2193-2201.
38. Ikei KN, Yeung J, Apopa PL, et al. Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. J Lipid Res 2012; 53: 2546-2559.
39. Konopatskaya O, Matthews SA, Harper MT, et al. Protein kinase C mediates platelet secretion and thrombus formation through protein kinase D2. Blood 2011; 118: 416-424.
40. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12: 261-273.
41. Deschamps JD, Kenyon VA, Holman TR. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem 2006; 14: 4295-4301.
42. Unsworth AJ, Smith H, Gissen P, et al. Submaximal inhibition of protein kinase C restores ADP-induced dense granule secretion in platelets in the presence of Ca2+. J Biol Chem 2011; 286: 21073-21082.
43. Margalit A, Granot Y. Endogenous hepoxilin A3, produced under short duration of high shear-stress, inhibits thrombin-induced aggregation in human platelets. Biochim Biophys Acta 1994; 1190: 173-176.
44. Margalit A, Sofer Y, Grossman S, et al. Hepoxilin A3 is the endogenous lipid mediator opposing hypotonic swelling of intact human platelets. Proc Natl Acad Sci USA 1993; 90: 2589-2592.
45. Italiano JE, Jr., Battinelli EM. Selective sorting of alpha-granule proteins. J Thromb Haemost 2009; 7 (Suppl 1): 173-176.
46. Singh NK, Kundumani-Sridharan V, Rao GN. 12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation. Blood 2011; 118: 5701-5712.
47. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
48. Dailey LA, Imming P. 12-Lipoxygenase: classification, possible therapeutic benefits from inhibition, and inhibitors. Curr Med Chem 1999; 6: 389-398.
49. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002; 90: 760-762.
50. Glading A, Koziol JA, Krueger J, et al. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 2007; 67: 1536-1544.
51. Jamieson DG, Parekh A, Ezekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther 2005; 10: 153-161.